Trial Profile
Phase I/II study of OSI-774 (erlotinib) and CCI-779 (temsirolimus) in patients with recurrent malignant glioma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 07 Jun 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 07 Jun 2012 Actual end date (Apr 2010 ) added as reported by ClinicalTrials.gov.